Yangonin

Yangonin is a kavalactone compound derived from the kava plant (Piper methysticum) that exerts effects primarily through cannabinoid CB1 receptor activation and monoamine oxidase B (MAO-B) inhibition. Its most studied properties include analgesic, anti-inflammatory, and anti-cancer activity, though human clinical evidence remains limited.

Origin & History

Yangonin is a kavalactone, a class of bioactive compounds isolated from the roots of Piper methysticum (kava plant), a shrub native to the South Pacific islands. It is typically extracted via solvent methods followed by high-performance liquid chromatography (HPLC) for purification and quantification in kava extracts. Chemically, yangonin belongs to the pyrone-based kavalactone family, characterized by a 4-methoxy-6-styryl-α-pyrone structure that confers receptor-binding properties.

Historical & Cultural Context

Yangonin is a constituent of kava (Piper methysticum), used traditionally in Pacific Island cultures (e.g., Vanuatu, Fiji) for centuries as a ceremonial beverage to induce relaxation, reduce anxiety, and promote sociability. While yangonin's specific role is not isolated in traditional use, kavalactones collectively contribute to kava's psychopharmacological effects.

Health Benefits

• May reduce pain and inflammation through CB1 receptor activation (preliminary evidence from animal studies)
• Shows potential anti-cancer effects in bladder cancer cell lines, inhibiting cell growth by 27.5% at 50 μg/mL (in vitro evidence only)
• May enhance chemotherapy effectiveness when combined with docetaxel, achieving 83.6% combined inhibition (preliminary cell culture data)
• Potentially protects against alcohol-induced liver cell aging via FXR activation (in vitro evidence)
• May contribute to anxiety-reducing effects as part of traditional kava preparations (traditional use, no yangonin-specific human trials)

How It Works

Yangonin binds to and activates the cannabinoid CB1 receptor, which modulates pain signaling and inflammatory cascades without producing psychoactive effects comparable to THC. It also inhibits monoamine oxidase B (MAO-B), an enzyme responsible for degrading dopamine, potentially contributing to mood-related effects. Additionally, yangonin has been shown to downregulate cell cycle progression proteins in bladder cancer cell lines, inhibiting proliferation through mechanisms that may involve p21 upregulation and cyclin-dependent kinase suppression.

Scientific Research

No human clinical trials, RCTs, or meta-analyses specifically on yangonin were identified in the available sources; evidence is limited to preclinical animal and in vitro studies. Animal studies in male Sprague-Dawley rats showed anti-nociceptive effects at intrathecal doses of 19.36 nmol/rat, while in vitro bladder cancer studies demonstrated growth inhibition and autophagy induction at concentrations up to 50 μg/mL.

Clinical Summary

Human clinical evidence for isolated yangonin is essentially nonexistent; available data come from in vitro cell studies and animal models. In bladder cancer cell line experiments, yangonin inhibited cell growth by approximately 27.5% at a concentration of 50 μg/mL, and demonstrated synergistic effects when combined with standard chemotherapeutic agents. Animal studies support analgesic and anti-inflammatory activity via CB1 receptor pathways, but doses and bioavailability in humans have not been established. The overall evidence base is preliminary, and no randomized controlled trials have evaluated yangonin as an isolated compound in humans.

Nutritional Profile

Yangonin is a kavalactone (specifically a methoxylated kavalactone) isolated from the rhizome of Piper methysticum (kava), not a nutritional food source. It is a bioactive secondary metabolite with the molecular formula C₁₅H₁₄O₄ and a molecular weight of approximately 258.27 g/mol. Typical concentration in kava root extracts ranges from approximately 1–3% of total kavalactone content, depending on cultivar and extraction method. It is structurally characterized by a 4-methoxy-substituted styryl group attached to an α-pyrone ring, distinguishing it from other kavalactones such as kavain, dihydrokavain, and methysticin. Yangonin is lipophilic (estimated LogP ~2.8–3.2), which contributes to its affinity for lipid membranes and cannabinoid receptors (notably CB1). It is not a source of macronutrients (protein, carbohydrates, or fats), vitamins, minerals, or dietary fiber. Bioavailability: As a lipophilic compound, oral absorption is enhanced when consumed with dietary fats or in lipid-based formulations. First-pass hepatic metabolism likely reduces systemic bioavailability; it is metabolized primarily via CYP450 enzymes (CYP3A4 and CYP2D6), producing demethylated and hydroxylated metabolites. Solubility in water is very low (~practically insoluble), but it dissolves readily in ethanol, acetone, and other organic solvents, which is why traditional aqueous kava preparations may contain lower yangonin concentrations compared to ethanolic or acetonic extracts. In standardized kava extracts (typically standardized to 30–70% total kavalactones), yangonin may constitute roughly 10–15% of the total kavalactone fraction, translating to approximately 3–10 mg per typical supplement dose depending on formulation.

Preparation & Dosage

No clinically studied dosages in humans are available for yangonin specifically. Preclinical intrathecal doses in rats were 19.36 nmol/rat, while in vitro cancer studies used 50 μg/mL. Kava extracts containing yangonin are typically standardized to total kavalactones via HPLC, but yangonin-specific standardization is not established. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Kavain, Methysticin, Dihydrokavain, Flavokavain A, Docetaxel

Safety & Interactions

Yangonin, like other kavalactones, carries a potential risk of hepatotoxicity, and high or prolonged intake of kava-derived products has been associated with liver damage in case reports. It may interact with drugs metabolized by cytochrome P450 enzymes, particularly CYP1A2 and CYP3A4, potentially altering blood levels of medications including anticoagulants and sedatives. Because yangonin inhibits MAO-B, combining it with MAO inhibitor medications or serotonergic drugs could pose an interaction risk. Kava-containing supplements, including those providing yangonin, are contraindicated during pregnancy and breastfeeding, and individuals with liver disease should avoid them entirely.